Implementation and safety of an outpatient bispecific T-cell engager program within a community oncology network
NCODA Oncology and Hematology Meeting Abstracts · 13.10.2026 · 2 (2)
DOI: 10.67209/jfjv2672 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 13.10.2026. Verfasst von Brooke Peters und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Initiation of bispecific T-cell engaging antibodies commonly includes hospital collaboration for the administration of or observation after step-up doses due to the risk of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). This study assesses the implementation and safety of an outpatient- only bispecific T-cell engager (BTCE) program in the community setting.
Objective
Determine if bispecific T-cell engagers may be administered safely in the outpatient setting by independent community oncology practices.
Method
A retrospective chart review was performed to evaluate implementation and safety of an outpatient-only BTCE program. Institutional standard operating procedures established a structured multidisciplinary workflow for drug administration, toxicity prevention, and CRS/ICANS monitoring and management during the step-up dosing period. Patients who received the first dose of any BTCE through an outpatient-only approach at American Oncology Network (AON) practices were included.
Results
A total of 66 patients were included, with underlying malignancies of extensive-stage small cell lung cancer, multiple myeloma, follicular lymphoma, diffuse large B-cell lymphoma, and uveal melanoma. Prophylactic tocilizumab was administered in 53 patients (80.3%). Overall, adherence to the institution-recommended outpatient monitoring and supportive care measures was high. CRS and ICANS were documented in 10 patients (15.2%) and 4 patients (6.1%), respectively, with all events classified as grade 1. During the first 30 days following therapy initiation, 3 patients (7.6%) required hospitalization related to CRS or ICANS.
Conclusions
These data support that a fully outpatient approach to administration and monitoring of BTCEs can be implemented safely in the community setting. Documented incidence of CRS and ICANS was low, and all events were grade 1. Many low-grade toxicities can be managed with supportive care at home or in an outpatient setting. Furthermore, healthcare resource utilization may be significantly decreased with an outpatient-only approach, with very few patients requiring hospitalization due to CRS/ICANS. Funding: Not applicable.
Zitieren
APA
Peters, B., Maksour, M., Perkey, C., McMullen, N., Carr, R., Laubenthal, A., & Chang, M. (2026). Implementation and safety of an outpatient bispecific T-cell engager program within a community oncology network. NCODA Oncology and Hematology Meeting Abstracts, 2(2). https://doi.org/10.67209/jfjv2672
Vancouver
Peters B, Maksour M, Perkey C, McMullen N, Carr R, Laubenthal A, et al. Implementation and safety of an outpatient bispecific T-cell engager program within a community oncology network. NCODA Oncology and Hematology Meeting Abstracts. 2026;2(2). doi:10.67209/jfjv2672
BibTeX
@article{Peters2026,
author = {Peters, Brooke and Maksour, Manale and Perkey, Cassandra and McMullen, Nicole and Carr, Robert and Laubenthal, Alison and Chang, Melody},
title = {Implementation and safety of an outpatient bispecific T-cell engager program within a community oncology network},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
volume = {2},
number = {2},
doi = {10.67209/jfjv2672}
}
EUVIMED